Current status of pharmacotherapy for primary sclerosing cholangitis
Primary sclerosing cholangitis (PSC) represents a cholestatic disease hallmarked by persistent and progressive inflammation of the bile ducts. Despite its low incidence and unfavorable prognosis, there is no pharmacological therapy capable of altering the course of PSC, and liver transplantation is...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1544601/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849419066180108288 |
|---|---|
| author | Hang Yang Juan Zhen Xiaoyan Huang Minqi Chen Hongsi Cui Xia Sheng Xinyu Li |
| author_facet | Hang Yang Juan Zhen Xiaoyan Huang Minqi Chen Hongsi Cui Xia Sheng Xinyu Li |
| author_sort | Hang Yang |
| collection | DOAJ |
| description | Primary sclerosing cholangitis (PSC) represents a cholestatic disease hallmarked by persistent and progressive inflammation of the bile ducts. Despite its low incidence and unfavorable prognosis, there is no pharmacological therapy capable of altering the course of PSC, and liver transplantation is the only effective treatment. In the face of the landscape of PSC, pharmaceutical therapy encounters great challenges that demand expeditious resolution. However, at present, many drugs have been carried out to phase III clinical trials and are expected to be applied to the clinical treatment of PSC patients in the future. This review integrates relevant research findings from PubMed and Web of Science databases up to October 2024 over the past decade, excluding other liver diseases, such as fatty liver disease, viral hepatitis, and alcoholic liver disease. It covers the vast majority of drugs currently in clinical trials, and focus on the summary of hot research drugs, and summarizes the latest drug-based therapeutic for PSC. This review not only provides certain information for clinical research and treatment of PSC, but it is also the first time that stem cell therapy has been linked to PSC, which is expected to improve cholestasis and liver inflammation in patients with PSC. The article provides explanations and comparisons of different drugs, offering a basis for future researchers to choose medications. |
| format | Article |
| id | doaj-art-bc1d32711f6e4088954bd6e922b4e4fd |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-bc1d32711f6e4088954bd6e922b4e4fd2025-08-20T03:32:15ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-06-011210.3389/fmed.2025.15446011544601Current status of pharmacotherapy for primary sclerosing cholangitisHang Yang0Juan Zhen1Xiaoyan Huang2Minqi Chen3Hongsi Cui4Xia Sheng5Xinyu Li6Department of Anesthesiology, The First Hospital of Jilin University, Changchun, Jilin, ChinaDepartment of Cadre Ward, The First Hospital of Jilin University, Changchun, Jilin, ChinaThe First Hospital of Jilin University, Changchun, Jilin, ChinaThe First Hospital of Jilin University, Changchun, Jilin, ChinaThe First Hospital of Jilin University, Changchun, Jilin, ChinaDepartment of Clinical Nutrition, China-Japan Union Hospital of Jilin University, Changchun, Jilin, ChinaDepartment of Intensive Care Medicine, The First Hospital of Jilin University, Changchun, Jilin, ChinaPrimary sclerosing cholangitis (PSC) represents a cholestatic disease hallmarked by persistent and progressive inflammation of the bile ducts. Despite its low incidence and unfavorable prognosis, there is no pharmacological therapy capable of altering the course of PSC, and liver transplantation is the only effective treatment. In the face of the landscape of PSC, pharmaceutical therapy encounters great challenges that demand expeditious resolution. However, at present, many drugs have been carried out to phase III clinical trials and are expected to be applied to the clinical treatment of PSC patients in the future. This review integrates relevant research findings from PubMed and Web of Science databases up to October 2024 over the past decade, excluding other liver diseases, such as fatty liver disease, viral hepatitis, and alcoholic liver disease. It covers the vast majority of drugs currently in clinical trials, and focus on the summary of hot research drugs, and summarizes the latest drug-based therapeutic for PSC. This review not only provides certain information for clinical research and treatment of PSC, but it is also the first time that stem cell therapy has been linked to PSC, which is expected to improve cholestasis and liver inflammation in patients with PSC. The article provides explanations and comparisons of different drugs, offering a basis for future researchers to choose medications.https://www.frontiersin.org/articles/10.3389/fmed.2025.1544601/fullprimary sclerosing cholangitisursodeoxycholic acidNor-UDCAclinical trialdrug therapy |
| spellingShingle | Hang Yang Juan Zhen Xiaoyan Huang Minqi Chen Hongsi Cui Xia Sheng Xinyu Li Current status of pharmacotherapy for primary sclerosing cholangitis Frontiers in Medicine primary sclerosing cholangitis ursodeoxycholic acid Nor-UDCA clinical trial drug therapy |
| title | Current status of pharmacotherapy for primary sclerosing cholangitis |
| title_full | Current status of pharmacotherapy for primary sclerosing cholangitis |
| title_fullStr | Current status of pharmacotherapy for primary sclerosing cholangitis |
| title_full_unstemmed | Current status of pharmacotherapy for primary sclerosing cholangitis |
| title_short | Current status of pharmacotherapy for primary sclerosing cholangitis |
| title_sort | current status of pharmacotherapy for primary sclerosing cholangitis |
| topic | primary sclerosing cholangitis ursodeoxycholic acid Nor-UDCA clinical trial drug therapy |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1544601/full |
| work_keys_str_mv | AT hangyang currentstatusofpharmacotherapyforprimarysclerosingcholangitis AT juanzhen currentstatusofpharmacotherapyforprimarysclerosingcholangitis AT xiaoyanhuang currentstatusofpharmacotherapyforprimarysclerosingcholangitis AT minqichen currentstatusofpharmacotherapyforprimarysclerosingcholangitis AT hongsicui currentstatusofpharmacotherapyforprimarysclerosingcholangitis AT xiasheng currentstatusofpharmacotherapyforprimarysclerosingcholangitis AT xinyuli currentstatusofpharmacotherapyforprimarysclerosingcholangitis |